In a Phase I/II trial, intramuscular administration of mRNA-4650 in CRC patients successfully induced CD8+ and CD4+ T cell responses against neoantigens, without significant adverse effects or tumor relapse [124]. The gene discussed is CD8A; the disease is neoplasm.